Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma
NCT03559764Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Jun 2018
- Primary completion
- Feb 2020
01
Overview
Phase 1, open-label, single-arm trial in multiple myeloma (MM), sponsored by Allife Medical Science and Technology. Primary endpoint: Cytokine Release Syndrome. Status: unknown.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03559764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559764.